Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia

Clinical Effectiveness, Adherence, Clinical and Paraclinical Outcomes Associated With Tenofovir Alafenamide/Emtricitabine/Bictegravir (TAF/FTC/BIC) in Patients Diagnosed With Human Immunodeficiency Virus HIV) in Colombia: A Real-Life Study

HIV remains a major global health issue, with 38 million people affected, and significant challenges in diagnosis and treatment due to stigma and socioeconomic factors. In Colombia, the epidemic is concentrated among men who have sex with men, with 165,405 people living with HIV and 14,670 new cases reported in 2023. Barriers to treatment access are exacerbated by social factors and Venezuelan migration. While integrase inhibitors like TAF/FTC/BIC have shown effectiveness, real-world data in Colombia is limited. This study evaluates adherence, effectiveness, and clinical outcomes of TAF/FTC/BIC in 169 patients within the EPS SURA program, contributing context-specific evidence.

Inclusion Criteria:

• Male or female patients aged 18 years or older.
• Individuals with a confirmed HIV diagnosis.
• Individuals enrolled in EPS SURA during the study period.
• Patients receiving treatment with the TAF/FTC/BIC regimen.

Exclusion Criteria:

• Patients with a concurrent diagnosis of tuberculosis.
• Pregnant patients during the study period.
• Patients with virologic failure.
• Patients who started treatment with TAF/FTC/BIC but changed providers or discontinued treatment before completing six months of therapy.